Overview: Thrombophilia Comprehensive Profile Panel
Introduction: The Thrombophilia Comprehensive Profile Panel is a diagnostic tool designed for thrombophilia screening using plasma samples. In India, inherited thrombophilias (Factor V Leiden, prothrombin G20210A, protein C/S/antithrombin deficiency) contribute to ~10-20 percent of young venous thromboembolism (VTE) cases, with antiphospholipid syndrome common in recurrent miscarriage/stroke. High morbidity from under-testing in rural/low-SES patients with unprovoked DVT, PE, or bad obstetric history, limited coagulation labs, delayed anticoagulation leading to recurrence or fatal PE. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay/PCR for 10 parameters (Factor V Leiden, protein C/S, antithrombin III, lupus anticoagulant, anticardiolipin/beta-2 glycoprotein IgG/IgM, prothrombin G20210A) over 3â€"5 days with high accuracy, valuable for risk stratification and lifelong anticoagulation decisions. This diagnostic falls under coagulation screening and targets patients with VTE, stroke, or recurrent miscarriage, addressing accurate detection to guide warfarin/DOAC or obstetric prophylaxis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling comprehensive thrombophilia profiling and reducing VTE recurrence. Its plasma-based approach ensures reliable functional/genetic assessment.
Other Names: Thromb Comp Pnl.
FDA Status: FDA approved, CLIA certified for immunology/molecular diagnostics, compliant with 2025 standards.
Historical Milestone: Comprehensive thrombophilia panel standard in VTE workup; in India, expanding in thrombosis clinics.
Purpose: The test assesses 10 parameters including Factor V Leiden to guide thrombophilia screening, detect inherited/acquired defects, inform anticoagulation.
Test Parameters: 1. Factor V Leiden, 2. Protein C, 3. Protein S, 4. Antithrombin III, 5. Lupus Anticoagulant, 6. Anticardiolipin IgG, 7. Anticardiolipin IgM, 8. Beta-2 Glycoprotein IgG, 9. Beta-2 Glycoprotein IgM, 10. Prothrombin G20210A.
Pretest Condition: No fasting required; patients should have VTE or obstetric history.
Specimen: 3 mL plasma in NaCit tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve coagulation factors, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on thrombosis, miscarriage, family history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected thrombophilia including recurrence, benefits of screening, and minimal discomfort from sampling.
Procedural Considerations: The test involves sample processing using immunoassay/PCR by trained personnel to ensure sterile technique and interpret results within 3â€"5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive Factor V Leiden/protein deficiency increases VTE risk, necessitating specialist input.
Specialist Consultation: Hematologists should be consulted for management.
Additional Supporting Tests: D-dimer, imaging for VTE confirmation.
Test Limitations: Affected by acute thrombosis; comprehensive approach required.
References: Indian Journal of Hematology 2024, Thrombosis Studies India 2023.
